# US 2012/0252771 A1 · Implants and methods for treating inflammation-mediated conditions of the eye

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252771 A1
- Document ID: US20120252771A1
- Status: Published application
- Kind: A1
- Application number: 13/494,591
- Filed: 2012-06-12
- Published: 2012-10-04
- Earliest claimed: 2000-07-05
- Assignees: Allergan, Inc.
- Inventors: Vernon G. WONG; Mae W.L. HU
- Web page: https://patentgrep.com/patent/US20120252771A1

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 9/0002: {Galenical forms characterised by the drug release technique; Application systems commanded by energy}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 5/38: of the suprarenal hormones
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.

## Claims

### Claim 1

A bioerodible implant for treating an inflammation-mediated condition of the eye, the implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, the implant structured to be placed in the vitreous of the eye and deliver the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.2 μg/ml dexamethasone within about 6 hours and maintain a concentration equivalent to at least about 0.01 μg/ml dexamethasone for at least about three weeks, wherein the steroidal anti-inflammatory agent is fluocinolone acetonide.

### Claim 2

A bioerodible implant for treating an inflammation-mediated condition of the eye, the implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, the implant structured to be placed in the vitreous of the eye and deliver the agent to the vitreous in an amount sufficient to reach an in vivo concentration equivalent to at least 0.05 μg/mL dexamethasone within about 48 hours and to maintain an in vivo concentration equivalent to at least about 0.03 μg/mL dexamethasone for at least about three weeks, wherein the total weight of the implant is about 250-5000 μg.

### Claim 3 (depends on 2)

The implant of claim 2, wherein the bioerodible polymer is a polylactic acid polyglycolic acid (PLGA) copolymer.

### Claim 4 (depends on 2)

The implant of claim 2, wherein the steroidal anti-inflammatory agent comprises about 10 to 90% by weight of the implant.

### Claim 5 (depends on 2)

The implant of claim 2, wherein the steroidal anti-inflammatory agent comprises about 50 to about 80% by weight of the implant.
